FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
Approved uses also being limited to certain patients
Previous
Previous
FDA’s National Center for Toxicological Research Celebrates Half a Century of Cutting-Edge Research
Next
Next